Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Non-Antiretroviral Microbicides for HIV Prevention.

Scott Y, Dezzutti CS.

AIDS Rev. 2016 Jul-Sep;18(3):145-150.

2.

Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates.

Abaasa A, Asiki G, Price MA, Ruzagira E, Kibengo F, Bahemuka U, Fast PE, Kamali A.

Vaccine. 2016 Apr 4;34(15):1778-85. doi: 10.1016/j.vaccine.2016.02.048.

3.

Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.

Eid SG, Mangan NE, Hertzog PJ, Mak J.

Clin Transl Immunology. 2015 Oct 9;4(10):e43. doi: 10.1038/cti.2015.23. Review.

4.

A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, Moncla BJ, Devlin B, Meyn LA, Spiegel HM, Hillier SL.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897.

PMID:
26565716
5.

Microbicides for the Treatment of Sexually Transmitted HIV Infections.

Singh O, Garg T, Rath G, Goyal AK.

J Pharm (Cairo). 2014;2014:352425. doi: 10.1155/2014/352425. Review.

6.

Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.

Friedland BA, Stoner M, Chau MM, Plagianos MG, Govender S, Morar N, Altini L, Skoler-Karpoff S, Ahmed K, Ramjee G, Monedi C, Maguire R, Lähteenmäki P.

AIDS Behav. 2016 Nov;20(11):2565-2577.

7.

Implementation of an electronic fingerprint-linked data collection system: a feasibility and acceptability study among Zambian female sex workers.

Wall KM, Kilembe W, Inambao M, Chen YN, Mchoongo M, Kimaru L, Hammond YT, Sharkey T, Malama K, Fulton TR, Tran A, Halumamba H, Anderson S, Kishore N, Sarwar S, Finnegan T, Mark D, Allen SA.

Global Health. 2015 Jun 27;11:27. doi: 10.1186/s12992-015-0114-z.

8.

Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.

Hijazi K, Cuppone AM, Smith K, Stincarelli MA, Ekeruche-Makinde J, De Falco G, Hold GL, Shattock R, Kelly CG, Pozzi G, Iannelli F.

PLoS One. 2015 Jun 23;10(6):e0131405. doi: 10.1371/journal.pone.0131405.

9.

Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.

Zalenskaya IA, Joseph T, Bavarva J, Yousefieh N, Jackson SS, Fashemi T, Yamamoto HS, Settlage R, Fichorova RN, Doncel GF.

PLoS One. 2015 Jun 8;10(6):e0128557. doi: 10.1371/journal.pone.0128557.

10.

Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.

Karim QA, Baxter C, Karim SA.

BJOG. 2014 Oct;121 Suppl 5:53-61. doi: 10.1111/1471-0528.12843. Review.

11.

Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.

Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SF, Snyder BA, Mankowski MK, Jones NM, Hope JL, Gupta P, Anderson SH, Wigdahl B, Katsikis PD.

Antimicrob Agents Chemother. 2014 Dec;58(12):7056-71. doi: 10.1128/AAC.02991-14.

12.

Topical microbicides and HIV prevention in the female genital tract.

Cottrell ML, Kashuba AD.

J Clin Pharmacol. 2014 Jun;54(6):603-15. doi: 10.1002/jcph.292. Review.

13.

Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, Grobler A, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):811-9. doi: 10.1007/s10461-014-0751-x.

14.

Who will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries?

Dimitrov DT, Masse B, Boily MC.

Stat Commun Infect Dis. 2010 Jan;2(1):1012.

15.

The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.

Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J; MDP team..

AIDS Behav. 2014 Feb;18(2):297-310. doi: 10.1007/s10461-013-0676-9.

16.

Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.

Gupta SK, Nutan.

HIV AIDS (Auckl). 2013 Oct 22;5:295-307. doi: 10.2147/HIV.S39164. Review.

17.

Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis.

Musekiwa A, Muchiri E, Manda SO, Mwambi HG.

PLoS One. 2013 Oct 10;8(10):e77014. doi: 10.1371/journal.pone.0077014. Review.

18.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah TN, Moosa A, Naidoo A, Mansoor LE.

Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Review.

19.

Unintended pregnancy among HIV positive couples receiving integrated HIV counseling, testing, and family planning services in Zambia.

Wall KM, Haddad L, Vwalika B, Htee Khu N, Brill I, Kilembe W, Stephenson R, Chomba E, Vwalika C, Tichacek A, Allen S.

PLoS One. 2013 Sep 30;8(9):e75353. doi: 10.1371/journal.pone.0075353.

20.

Cross-sectional HIV incidence estimation in HIV prevention research.

Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S233-9. doi: 10.1097/QAI.0b013e3182986fdf.

Items per page

Supplemental Content

Support Center